Brief: Ikena Oncology Announces FDA Acceptance Of IND Application Of Novel TEAD Inhibitor IK-930
02/11/2021 13:12
Nov 2 (Reuters) - Ikena Oncology Inc IKNA.O :
* IKENA ONCOLOGY ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION
OF
NOVEL TEAD INHIBITOR IK-930
Source text for Eikon: ID:nGNXb5Hczd
Further company coverage: IKNA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on ImageneBio
See all newsU.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Brief: ImageneBio Inc - On Oct 23, Elects Not To Renew Agreement With Miragene - SEC Filing
ImageneBio Inc expected to post a loss of $1.56 a share - Earnings Preview
Brief: Ikena Oncology Announces Stockholder Approval Of Merger With Inmagene Biopharmaceuticals